Esoteric Testing Market Report 2025

The esoteric testing market size has grown rapidly in recent years. It will grow from $32.93 billion in 2024 to $36.71 billion in 2025 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to advancements in biotechnology, rising chronic diseases, precision medicine evolution, increased focus on rare diseases, genomic discoveries.

The esoteric testing market size is expected to see rapid growth in the next few years. It will grow to $59.58 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to demand for early disease detection, expanding geriatric population, precision oncology growth, expansion of rare disease research, global health challenges. Major trends in the forecast period include liquid biopsies and circulating biomarkers, microbiome analysis, ai and machine learning integration, point-of-care esoteric testing, expanded genetic and molecular testing.

The rising incidence of infectious diseases is anticipated to drive the growth of the esoteric testing market in the future. Infectious diseases arise from pathogens like bacteria and viruses, influenced by factors such as migration, travel, and environmental changes. Esoteric testing employs advanced technologies, such as nucleic acid technology, which can detect the genetic material of infectious agents, offering more accurate and sensitive results compared to traditional methods like microbiological culture. For example, in August 2024, the UK Health Security Agency (UKHSA), a UK-based executive agency, reported 368 measles cases in England for 2023, representing a nearly sevenfold increase from the 53 cases documented in 2022, with the West Midlands and London responsible for 44% and 33% of the cases, respectively. Thus, the increasing prevalence of infectious diseases is propelling the growth of the esoteric testing market.

The growing geriatric population is expected to boost the growth of the esoteric testing market in the coming years. The geriatric population consists of elderly individuals, typically aged 65 and older, and is characterized by specific health and social needs. As this demographic continues to expand, the esoteric testing market plays a vital role in improving healthcare diagnostics and personalized medicine, ultimately enhancing medical management and overall well-being for older adults. For example, in January 2023, the United Nations Department of Economic and Social Affairs (UN DESA), a US-based department of the UN Secretariat, reported that the global population of individuals aged 65 and older is projected to more than double, rising from 761 million in 2021 to 1.6 billion by 2050. Thus, the increasing geriatric population is driving the esoteric testing market.

Technological advancements are a significant trend gaining traction in the esoteric testing market. Major companies within this sector are creating innovative solutions based on advanced technologies to maintain their competitive edge. For example, in June 2023, Kephera Diagnostics, LLC, a medical diagnostics company based in the U.S., announced the launch of CLIA laboratory tests for three parasitic diseases: Chagas disease, neurocysticercosis, and liver fluke infection. This enhancement of their testing capabilities builds on their existing tests for Lyme disease and aims to improve the diagnosis of underrecognized parasitic infections in the U.S. The company introduced two tests for Chagas disease, including an FDA-approved ELISA and a multiplex test that detects antibodies to the parasite.

Companies in the esoteric testing market are particularly focused on product launches, such as automated chemiluminescent enzyme immunoassay analyzers, to improve assay analytical specifications, enhance user-friendliness, and boost analytical performance. An automated chemiluminescent enzyme immunoassay analyzer is an advanced laboratory instrument utilizing chemiluminescent reactions and enzyme immunoassay techniques for automated and highly sensitive biomolecule detection. For instance, in May 2023, Tosoh Bioscience - Diagnostics EMEA, a Japan-based company, introduced the AIA-CL300, a new compact automated chemiluminescent enzyme immunoassay analyzer. This launch emphasizes enhanced sensitivity, improved workflow automation, versatility for laboratories of varying sizes, predictable consumption, calibration stability, and user-friendly features to prevent errors. These attributes collectively address the specific needs of the esoteric testing market, ensuring precise and reliable detection of low abundance biomarkers while streamlining processes and maintaining consistent performance for accurate and reproducible results.

In March 2023, Quest Diagnostics, a U.S.-based medical laboratory company, acquired Northern Light Laboratory for an undisclosed sum. Following this acquisition, Quest Diagnostics intends to improve access to a wider array of innovative diagnostic tests, enhance laboratory management services, and reduce out-of-pocket expenses for patients and physicians across Maine. Northern Light Laboratory is a U.S.-based lab that offers analyses and diagnostic tests.

Major companies operating in the esoteric testing market include LabCorp Holdings, Quest Diagnostics Inc., Eurofins Scientific SE, Sonic Healthcare Limited, Miraca Holdings Inc., H.U. Group Holdings Inc., Arup Laboratories Inc., OPKO Health Inc., Mayo Medical Laboratories, SYNLAB International GmbH, Myriad Genetics Inc., Bio-Reference Laboratories Inc., NeoGenomics Laboratories, Foundation Medicine Inc., Health Network Laboratories, Fulgent Genetics Inc., Grifols S.A., Adaptive Biotechnologies Corporation, Genova Diagnostics, Kind star Globalgene Technology Inc., National Medical Services Inc. (NMS), ACM Global Laboratories LLC, Miraca Life Sciences Inc., Leo Labs Inc., Pacific Bio labs Inc., Lab21 Healthcare Ltd., HealthQuest Esoterics Inc., Georgia Esoteric And Molecular Laboratory LLC., Atherotech Diagnostics Lab, Spectra Laboratories Inc.

North America was the largest region in the esoteric testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the esoteric testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the esoteric testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Esoteric testing pertains to the laboratory examination of uncommon molecules and substances that are not typically analyzed in routine clinical laboratory procedures. This specialized testing is employed for the diagnosis and management of rare, complex, or unusual medical conditions that cannot be easily identified through standard laboratory tests.

The types of esoteric testing include infectious diseases testing, endocrinology testing, oncology testing, genetics testing, toxicology testing, immunology testing, neurology testing, and others. These tests utilize various technologies such as chemiluminescence immunoassay, enzyme-linked immunosorbent assay, mass spectrometry, real-time PCR, DNA (deoxyribonucleic acid) sequencing, flow cytometry, and others. Esoteric testing is conducted by independent and reference laboratories, as well as hospital-based laboratories.

The esoteric testing market research report is one of a series of new reports that provides esoteric testing market statistics, including the esoteric testing industry's global market size, regional shares, competitors with esoteric testing market share, detailed esoteric testing market segments, market trends and opportunities, and any further data you may need to thrive in the esoteric testing industry. This esoteric testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The esoteric testing market consists of revenues earned by entities by providing biochemical genetic tests, cytogenetic tests, and special coagulation tests, along with sample collection and diagnosis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The esoteric testing market also includes the sales of immunoassays, DNA (deoxyribonucleic acid) sequencing kits, immunoassays, chromatography systems, mass spectrometers, and PCR (polymerase chain reaction) kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.